title: Esomeprazole: a proton pump inhibitor.
abstract: Proton pump inhibitors (PPIs) are the most potent inhibitors of gastric acid secretion available, and they are effective for treating all acid-related disorders. Esomeprazole is one of several most recent PPIs that became available to the market in 2001. Esomeprazole is indicated for the treatment of gastroesophageal reflux disease in adults and children, risk reduction of NSAIDs-associated gastric ulcer, Helicobacter pylori eradication and control of pathological hypersecretory conditions associated with Zollinger-Ellison syndrome. Esomeprazole is available in both oral and intravenous formulations. A number of studies have compared esomeprazole with other PPIs. While differences supporting esomeprazole have been reported, the magnitude of differences has been variable and of uncertain clinical importance. Cost plays a major role in prescribing patterns of PPIs.
authors.affiliation: Virginia Commonwealth University, PO Box 980341, Richmond, VA 23298, USA. rvachhani@mcvh-vcu.edu
authors.forename: Ravi
authors.initials: R
authors.lastname: Vachhani
authors.forename: Gregory
authors.initials: G
authors.lastname: Olds
authors.forename: Vic
authors.initials: V
authors.lastname: Velanovich
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D016527:Drug Costs; D064098:Esomeprazole / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D016481:Helicobacter Infections / Q000188:drug therapy; D006801:Humans; D054328:Proton Pump Inhibitors / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D013276:Stomach Ulcer / Q000139:chemically induced / Q000188:drug therapy
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D054328:Proton Pump Inhibitors; D064098:Esomeprazole